A2B
Alpha-2-agonists for sedation to produce better outcomes from critical illness: A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost- effectiveness
Last updated
Was this helpful?
Alpha-2-agonists for sedation to produce better outcomes from critical illness: A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost- effectiveness
Last updated
Was this helpful?
Population: Ventilated patients within 48 hours of initiation of mechanical ventilation
Interventions: Clonidine ± opioid analgesic or Dexmedetomidine ± opioid analgesic
Comparison: Usual care sedation with propofol ± opioid analgesic
Outcome: Time from randomisation to successful extubation
Inclusion criteria
Exclusion criteria
Aged ≥18
Requiring ventilation
Within 48 hours of first episode of ventilation in ICU
Requiring sedation with propofol
Expected to require >48 hours of MV
Expected to require >24 hours of MV at the time of randomisation
Acute brain injury
Post-cardiac arrest
Status epilepticus
Continuous NMB at the time of screening/randomisation
Guillain-Barre Syndrome
Myasthenia gravis
Home ventilation
Fulminant hepatic failure
Not expected to survive 24 hours
Palliative or end-of-life care
Pregnancy
Known allergy to study drugs
Heart rate <50 for >60mins since ventilated
Untreated 2nd/3rd degree heart block
Transferred from another ICU where ventilated >6 hours hours
Prisoners
Enrolled on another CTIMP
Previously enrolled on the A2B Trial
Principle investigator: Dan Harvey
DREEAM: Julia Sampson
Trainee-lead:
Website:
